Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CELLSEARCH® CTC Test, which allows for an assessment of patient prognosis.
Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CELLSEARCH® CTC Test.
The CELLSEARCH® Circulating Tumor Cell (CTC) Test is the only technology cleared by the FDA. In order to be cleared by the FDA, Liu says, the CELLSEARCH test met metrics for being reproducible and user-friendly.
From a single tube of the patient's blood, the number of CTCs are counted in an automated and reproducible way. The number of CTCs can be anywhere from zero to tens or hundreds of thousands, Liu says, though the absolute number is not what matters. Patients with fewer than five CTCs have a favorable prognosis, while greater than or equal to five is unfavorable. The CELLSEARCH test allows for an assessment of patient prognosis and is predictive of progression-free survival and overall survival.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More